Research into the control the synthesis of nanoparticle structures that interface with biological systems in order to develop exquisitely targeted, practical, safe, and effective therapeutics, imaging agents, and biosensors for cancer and other diseases.
Labs In This Research Area
Focusing on the biology of neural stem cells and growth factors and their potential for regenerating the damaged or diseased nervous system.
The Kessler laboratory focuses on the biology of neural stem cells and growth factors and their potential for regenerating the damaged or diseased nervous system. A major interest of the laboratory has been the role of bone morphogenetic protein (BMP) signaling in both neurogenesis and gliogenesis and in regulating cell numbers in the developing nervous system. Both multipotent neural stem cells and pluripotent embryonic stem cells are studied in the laboratory, and recent efforts have emphasized studies of human embryonic stem cells (hESC) and human induced pluripotent stem cells (hIPSC). The Kessler lab oversees the Northwestern University ESC and IPSC core, and multiple collaborators use the facility. In addition to the studies of the basic biology of stem cells, the laboratory seeks to develop techniques for promoting neural repair in animal models of spinal cord injury and stroke. In particular the lab is examining how stem cells and self-assembling peptide amphiphiles can be used together to accomplish neural repair. The lab is also using hIPSCs to model Alzheimer’s disease and other disorders.
For more information see the faculty profile of John A Kessler, MD.
View Dr. Kessler's full list of publications in PubMed.
Elucidation of mechanisms of pathogenesis and immune regulation of autoimmune disease, allergy and tissue/organ transplantation
The laboratory is interested in understanding the mechanisms underlying the pathogenesis and immunoregulation of T cell-mediated autoimmune diseases, allergic disease, and rejection of tissue and organ transplants. In particular, we are studying the therapeutic use of short-term administration of costimulatory molecule agonists/antagonists and specific immune tolerance induced by infusion of antigen-coupled apoptotic cells and PLG nanoparticles for the treatment of animal models of multiple sclerosis and type 1 diabetes, allergic airway disease, as well as using tolerance for specific prevention of rejection of allogeneic and xenogeneic tissue and organ transplants.
Promising Results in Early Trial of Novel MS Treatment: Listen to a Science Friday interview with Dr. Miller regarding the Phase 1 clinical trial in multiple sclerosis patients. Read the article in Science Translational Medicine Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.
For lab information and more, see Dr. Miller's faculty profile.
See Dr. Miller's publications on PubMed.
Contact Dr. Miller at 312-503-7674 or the lab at 312-503-1449.
Defining and targeting the oncogenome of Glioblastoma.
Our research program is aimed at understanding the genetic program that underlies the pathogenesis of Glioblastoma multiforme (GBM), the most prevalent and malignant form of brain cancer. Applying a combination of cell/molecular biology, oncogenomic and mouse engineering approaches, we are dedicated to systematically characterize novel gliomagenic oncogenes and tumor suppressors. We will functionally delineate and validate these pathways using cell culture and animal models, and develop novel nanotechnological approaches to target these aberrations in established tumors.
View Dr. Stegh's full list of publications at PubMed
Alexander Stegh, MD, PhD, at 312-503-2879
Timothy L. Sita (MSTP)
Andrea E. Calvert (DGP)
Carissa M. Ritner (DGP)
Research Technician/Lab Manager
Lisa M. Hurley
Studying translational bio-nanotechnology
The Thaxton Lab focuses on the synthesis, characterization, and application of biomimetic nanoparticles for developing next generation biosensors and therapies. Disease processes where nanotherapies are being applied include cardiovascular disease and cancer.
For more information, see the faculty profile of C. Shad Thaxton, MD, PhD
View Dr. Thaxton's publications at PubMed
Nick Angeloni, Kannan Mutharasan, Jonathan Rink
Kaylin M. McMahon, Michael Plebanek, Sushant Tripathy, Andrea Luthi
Studying radiation-induced mutations in radiation-induced cancers; DNA-TiO2 nanoparticles; Radiosensitivity/motor neuron disease.
The Woloschak Lab members focus their research on three main areas.
The Janus Project: Studying radiation-induced mutations in radiation-induced cancers
This 30 year, $200 million set of experiments were performed at 150 laboratories, and then terminated before the data were completely analyzed. Funded by the Department of Energy and National Aeronautic and Space Administration, department radiobiologists will continue the data analyses.
Members of the Woloschak laboratory have assumed responsibility from Argonne National Laboratory for archiving tissue associated with 30,000 mice and 4,000 dogs that received various doses and dose-rates of radiation.
These studies examined the effects of dose-rate on radiation-induced toxicities and radiation-induced cancer. They are analyzing cancer cells from these tissues to find differences in mutational spectra that occur in tumors induced in radiation-exposed animals compared to those that occur in spontaneous tumors. Recent scientific concerns about very low dose exposures makes this effort particularly important.
- University of Chicago
- Bundewehr Radiobiology Institute in Munich
- Argonne National Lab
The researchers have combined the functional properties of the biomolecule DNA and the inorganic compound TiO2. The project is oriented to investigating the functional use of these nanocomposites for intracellular manipulation, imaging, and gene silencing.
Radiosensitivity/motor neuron disease
The project's purpose is to better understand the molecular basis for the combined abnormalities from a molecular-cellular perspective. Chipbased mRNA studies, gene promotoer analyses, immunohistochemistry, and standard molecular approaches are being used.
Contact Woloschak Lab
Contact Dr. Woloschak at 312-503-4323 or via email.